Literature DB >> 12759246

Heparin inhibits the motility and proliferation of human myometrial and leiomyoma smooth muscle cells.

Holly R Mason1, Romana A Nowak, Cynthia C Morton, John J Castellot.   

Abstract

Uterine fibroids (leiomyomas) are a major women's health problem. Currently, the standard for treatment remains hysterectomy, because no other treatment modalities can reduce both symptoms and recurrence. As leiomyomas are a hyperproliferation of smooth muscle cells, we sought to understand the regulation of uterine smooth muscle cell mitogenesis by the glycosaminoglycan heparin, which has been extensively studied as an anti-proliferative molecule in vascular smooth muscle cells. Using matched pairs of human myometrial and leiomyoma smooth muscle cells from the same uterus, we demonstrate that the proliferation and motility of both cell types are inhibited by heparin. We report that the decrease in cell number seen in the presence of heparin is not because of cell death. Interestingly, there is significant patient-to-patient variability in the proliferation response but not in the motility response to heparin. Furthermore, nonanticoagulant and anticoagulant heparin were equally effective at inhibiting leiomyoma and myometrial smooth muscle cell proliferation. These results warrant further investigation into the possibility that heparin might be useful in the treatment of uterine fibroids.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12759246      PMCID: PMC1868134          DOI: 10.1016/S0002-9440(10)64323-4

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  38 in total

1.  Clinical significance of cytogenetic abnormalities in uterine myomas.

Authors:  I Brosens; J Deprest; P Dal Cin; H Van den Berghe
Journal:  Fertil Steril       Date:  1998-02       Impact factor: 7.329

2.  Cytogenetic abnormalities in uterine myomas are associated with myoma size.

Authors:  M S Rein; W L Powell; F C Walters; S Weremowicz; R M Cantor; R L Barbieri; C C Morton
Journal:  Mol Hum Reprod       Date:  1998-01       Impact factor: 4.025

3.  Variation in the incidence of uterine leiomyoma among premenopausal women by age and race.

Authors:  L M Marshall; D Spiegelman; R L Barbieri; M B Goldman; J E Manson; G A Colditz; W C Willett; D J Hunter
Journal:  Obstet Gynecol       Date:  1997-12       Impact factor: 7.661

4.  Heparin rapidly and selectively regulates protein tyrosine phosphorylation in vascular smooth muscle cells.

Authors:  K Mishra-Gorur; J J Castellot
Journal:  J Cell Physiol       Date:  1999-02       Impact factor: 6.384

5.  Heparin inhibits proliferation of myometrial and leiomyomal smooth muscle cells through the induction of alpha-smooth muscle actin, calponin h1 and p27.

Authors:  A Horiuchi; T Nikaido; Z Ya-Li; K Ito; A Orii; S Fujii
Journal:  Mol Hum Reprod       Date:  1999-02       Impact factor: 4.025

6.  Inhibition of serum-induced proliferation of bovine tracheal smooth muscle cells in culture by heparin and related glycosaminoglycans.

Authors:  S A Kilfeather; S Tagoe; A C Perez; K Okona-Mensa; R Matin; C P Page
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

Review 7.  Emerging roles of caspase-3 in apoptosis.

Authors:  A G Porter; R U Jänicke
Journal:  Cell Death Differ       Date:  1999-02       Impact factor: 15.828

Review 8.  Heparin sensitive and resistant vascular smooth muscle cells: biology and role in restenosis.

Authors:  J D San Antonio; A Verrecchio; L A Pukac
Journal:  Connect Tissue Res       Date:  1998       Impact factor: 3.417

9.  Heparin inhibits human coronary artery smooth muscle cell migration.

Authors:  M Kohno; K Yokokawa; K Yasunari; M Minami; H Kano; A K Mandal; J Yoshikawa
Journal:  Metabolism       Date:  1998-09       Impact factor: 8.694

10.  Heparin and PGE2 inhibit DNA synthesis in human airway smooth muscle cells in culture.

Authors:  P R Johnson; C L Armour; D Carey; J L Black
Journal:  Am J Physiol       Date:  1995-10
View more
  6 in total

1.  CCN5, a secreted protein, localizes to the nucleus.

Authors:  Kristina C Wiesman; Lan Wei; Cassandra Baughman; Joshua Russo; Mark R Gray; John J Castellot
Journal:  J Cell Commun Signal       Date:  2010-03-18       Impact factor: 5.782

2.  Heparin in interventional radiology: a therapy in evolution.

Authors:  Stuart B Resnick; Stephanie H Resnick; Joshua L Weintraub; Nishita Kothary
Journal:  Semin Intervent Radiol       Date:  2005-06       Impact factor: 1.513

3.  The morphofunctional pattern of neuronal biogenic amines in postpartum involution period-an in vivo study.

Authors:  Hao Gu; Sergey V Dindyaev; Narasimha M Beeraka; Denis V Kasatkin; Elizaveta V Mikhaylenko; Junqi Liu; Cecil Eric Kirkland; Gjumrakch Aliev; Siva G Somasundaram; Cristian Muresanu; Ruitai Fan
Journal:  Histol Histopathol       Date:  2021-09-30       Impact factor: 2.303

4.  Growth inhibition of bovine pulmonary artery smooth muscle cells following long-term heparin treatment.

Authors:  Hicham Mrabat; Hari G Garg; Charles A Hales
Journal:  J Cell Physiol       Date:  2009-12       Impact factor: 6.384

5.  Combination therapy of heparin-deoxycholic acid conjugate and doxorubicin against squamous cell carcinoma and B16F10 melanoma.

Authors:  Kyeongsoon Park; Gee Young Lee; Rang-Woon Park; In-San Kim; Sang Yoon Kim; Youngro Byun
Journal:  Pharm Res       Date:  2007-07-11       Impact factor: 4.200

6.  Acetylation may strengthen the antitumor activity of low molecular heparin.

Authors:  Ying Liang; Guixin Duan; Yuanyuan Wang; Guowen Wang; Ansheng Wang; Kangwu Wang
Journal:  Transl Cancer Res       Date:  2021-01       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.